15 December 2023
15 December 2023
Low diversity data reporting rates in DCTs using ePROs point to missed opportunities to embrace patient preferences and racial backgrounds.
mRNA-4157 (V940) plus Keytruda reduced the disease recurrence or mortality risk by 49% versus Keytruda alone.
Reneo’s mavodelpar failed to meet its endpoints in the Phase III trial in primary mitochondrial myopathies, a rare genetic disorder.
The company plans to enrol 22 patients into an ongoing trial to assess pharmacokinetics in brain tissue with data expected in Q2 2024.
The positive results from the feasibility study will support the design and planning of an upcoming pivotal trial in Europe and the US.
The deal marks the fifth acquisition for the company since its inception in 2021 and brings millions more potential patients into its catchment area.
In the trial, 78% of subjects who received 100µg or 200µg MM-120 attained clinical response versus 31% in placebo.
Tolerability and safety of the treatment will be evaluated as the trial’s primary endpoints.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
